Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.34 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857265 | 0.84 | SMN1; SMN2 (0.46) | FABP3SMN1; SMN2ADRA1ALMNAESR1 | |
| SCHEMBL100728 | 0.84 | FABP3 (0.39) | FABP3SMN1; SMN2ADRA1ALMNAESR1 | |
| SCHEMBL29128926 | 0.83 | LPAR3 (0.50) | FABP3SMN1; SMN2ADRA1ALMNAESR1 | |
| SCHEMBL13619233 | 0.82 | FABP3 (0.39) | FABP3SMN1; SMN2ADRA1ALMNAESR1 | |
| SCHEMBL174096 | 0.80 | BTN3A1 (0.40) | SMN1; SMN2BTN3A1TSHRLPAR2LPAR3 | |
| SCHEMBL22568210 | 0.80 | LPAR3 (0.60) | FABP3ADRA1ALMNAESR1ADORA3 | |
| SCHEMBL4641076 | 0.79 | LPAR3 (0.36) | BTN3A1TSHRLPAR2LPAR3 | |
| SCHEMBL8598240 | 0.79 | FABP3 (0.37) | FABP3SMN1; SMN2ADRA1ALMNAESR1 | |
| SCHEMBL13745842 | 0.79 | FABP3 (0.43) | FABP3SMN1; SMN2ADRA1ALMNAESR1 | |
| SCHEMBL170993 | 0.79 | LMNA (0.56) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1807 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4312951-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF NUCLEIC ACID-ENCAPSULATED PARTICLES | Celanese EVA Performance Polymers LLC (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117120020-A | Implantable medical device for delivery of nucleic acid encapsulated particles | 塞拉尼斯伊娃高性能聚合物公司 | 2023-11-24 | — | — | CN | claimed |
| US-20220389160-A1 | EFFECTIVE INTRANASAL DELIVERY TO BRAIN | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2022-12-08 | — | — | US | claimed |
| US-20220313616-A1 | Implantable Medical Device for the Delivery of Nucleic Acid-Encapsulated Particles | CELANESE EVA PERFORMANCE POLYMERS LLC | 2022-10-06 | — | — | US | claimed |
| CN-114641517-A | Effective brain delivery technology by nasal administration | 汉阳大学校产学协力团 | 2022-06-17 | — | — | CN | claimed |
| US-20220168325-A1 | METHODS TO PROMOTE CEREBRAL BLOOD FLOW IN THE BRAIN | THE UNIVERSITY OF VERMONT | 2022-06-02 | — | — | US | claimed |
| US-11300572-B2 | Methods and systems for producing nanolipoprotein particles | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2022-04-12 | — | — | US | claimed |
| US-10864169-B2 | Conjugated polymer nanoparticles and manufacturing method thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2020-12-15 | — | — | US | claimed |
| WO-2020198037-A1 | METHODS TO PROMOTE CEREBRAL BLOOD FLOW IN THE BRAIN | THE UNIVERSITY OF VERMONT (US) | 2020-10-01 | — | — | WO | claimed |
| US-10752606-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD. (AU) | 2020-08-25 | — | — | US | claimed |
| CN-1052878-C | Stabilised hexadecylphosphocholine solutions in glycerol alkyl ethers | ASTA MEDICAL AKTIENGESELLSCHAF (DE) | 2000-05-31 | — | — | CN | claimed |
| US-6028209-A | REACTING A FATTY ALCOHOL WITH PHOSPHORUS OXYCHLORIDE IN A SINGLE VESSEL PROCESS, THEN REACTING WITH CHOLINE SALT TO FORM PHOSPHORIC ACID DIESTER CHLORIDE, HYDROLYSIS AND ISOLATION | ASTA MEDICA AG (DE) | 2000-02-22 | — | — | US | claimed |
| US-5942639-A | REACTING A C14-C18 N-ALKANOL WITH PHOSPHORUS OXYCHLORIDE THEN REACTING THE PRODUCT WITHOUT ISOLATION OR PURIFICATION WITH A CHOLINE SALT IN THE PRESENCE OF A BASE TO FORM THE PHOSPHORIC ACID DIESTER CHLORIDE, HYDROLYSING; MIXED BED ION EXCHANGING | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-08-24 | — | — | US | claimed |
| EP-0858807-A2 | Use of dopamine receptor antagonists in palliative tumor therapy | ASTA Medica Aktiengesellschaft (DE) | 1998-08-19 | — | — | EP | claimed |
| EP-0521297-B1 | Process for the preparation of alkylphosphocholines and purification thereof | ASTA MEDICA AG (DE) | 1997-09-17 | — | — | EP | claimed |
| EP-0593897-B1 | Stabilized solutions of alkylphosphocholine in glycerolalkylether | ASTA MEDICA AG (DE) | 1996-04-17 | — | — | EP | claimed |
| US-5446033-A | Antitumor agent; storage stability, antiseptic, chemical resistance, by-product inhibition | ASTA MEDICA AG (DE) | 1995-08-29 | — | — | US | claimed |
| CN-1090174-A | Stabilisation HEXADECYL PHOSPHOCHOLINE solution in the glycerol alkyl ether | ASTA MEDICA AG (DE) | 1994-08-03 | — | — | CN | claimed |
| EP-0593897-A1 | Stabilized solutions of alkylphosphocholine in glycerolalkylether | ASTA Medica Aktiengesellschaft (DE) | 1994-04-27 | — | — | EP | claimed |
| EP-0521297-A1 | Process for the preparation of alkylphosphocholines and purification thereof | ASTA Medica Aktiengesellschaft (DE) | 1993-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389160-A1 | EFFECTIVE INTRANASAL DELIVERY TO BRAIN | ADCYAP1R1, PCNP, CNP | FABP3 3792/4885SMN1; SMN2 271/4885ADRA1A 2766/4885 |
| US-10752606-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | FABP3 4474/4885SMN1; SMN2 3002/4885ADRA1A 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.